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onstruction and evaluation of vaccine candidate ﬁmH/ﬂiC
gainst Escherichia coli urinary tract infection
. Asadi Karam ∗, M. Oloomi, M. Habibi, S. Bouzari
Pasteur institute of Iran, Tehran, Iran, Islamic Republic of
Background: Urinary tract infection (UTI) is one of the most
ommon infections. Uropathogenic E.coli (UPEC) is the most fre-
uent cause of UTI. Adhesion FimH and ﬂagellin (FliC) are the
mportant virulence factors of UPEC. To date, any ideal vaccine
gainst UTI has not been approved for human use and we need
o test new target antigens to develop an ideal vaccine against UTI.
e constructed recombinant fusion FimH/FliC of UPEC as a novel
accine candidate against UTI.
Methods: UPEC were isolated from the UTI patients. The ﬁmH
nd ﬂiC genes were ampliﬁed by PCR. Construction of ﬁmH-ﬂiC
usion was performed by overlap PCR and the fusion cloned in
ET28a vector. The conﬁrmation of expression of the proteins was
one by SDS-PAGE and Western blot. The puriﬁcation of the pro-
einwas performed by afﬁnity chromatography. LPS removal of the
roteinwas done by using the Triton X114. Groups of 12micewere
mmunized on day 0, 14 and 28 with and without adjuvant (mon-
anide). The total IgG responses to FimH and FliC were evaluated
y ELISA.
Results:TheﬂiC andﬁmHgeneswere ampliﬁed in all of theUPEC
trains tested.Wegenerated a fusionprotein consisting of the FimH
rotein linked to the N-terminal of FliC that Sequencing conﬁrmed
he sequence. SDS-PAGE and western blot conﬁrmed the expres-
ion of the protein. The total IgG response to FimH in fusion form
as equal to response induced by FimH emulsiﬁed in montanide
djuvant. But, IgG response to FliCwas signiﬁcant in Fusion and FliC
roups with and without adjuvant.
Conclusion: UTIs are the second most common infectious dis-
ase. With an increasing number of UTIs being caused by antibiotic
esistant UPEC, there is a need for alternatives such as vaccina-
ion. Some of the virulence factors of UPEC have been tested as
accine against UTI that have limited success. Perhaps FimH could
e promisingmolecule that incorporation of FliC as a TLR5 ligand to
imH in Fusion form couldmake itmore potent vaccine. The results
f IgG responses showed that the fusion can be ideal vaccine candi-
ate against UTI. Other evaluations including cytokine assays and
hallenge of mice are in progress.
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Background: A recombinant, live, attenuated, tetravalent
denguevaccine (CYD-TDV) is in phase III efﬁcacy evaluation in Latin
America and South East Asia with a 3-dose 0–6–12 month regi-
men. Safety and immunogenicity to 28 days after vaccination has
previously been reported. Here we present the ﬁrst antibody per-
sistence and safety follow-up data from a group of 80 children and
adults who received 3 CYD-TDV doses at Months 0–3.5–12 as part
of a previously reported Phase 1 study in the Philippines (Capeding.
Vaccine 29, 3863-72).
Methods: Follow-up visits are being performed annually to
measure dengue neutralizing antibody responses (PRNT50). In
case of febrile illness (≥38 ◦C for ≥48h) at any time, participants
returned to the centre for laboratory diagnosis of suspected dengue
cases inacuteandconvalescentbloodsamples:denguePCR,dengue
NS1 antigen, IgM and IgG ELISA assays.
Results: Seventy-nine individuals participated in the follow-up
to Year 3. Twenty-eight days after the third vaccination, 88% were
seropositive (titer≥10) to all 4 serotypes and geometricmean titers
(GMTs) against dengue 1–4 were, respectively, 162, 300, 316, and
232. At the ﬁrst annual follow-up visit 11 months later, GMTs were
85, 206, 200, and 164. GMTs then remained stable until year 3
(respectively 80.5, 184, 180, 163), when 75% were still seroposi-
tive against all 4 serotypes. No SAEs and no severe dengue cases
were reported. Two virologically-conﬁrmed dengue cases (dengue
NS1 antigen positive) occurred in this cohort during these 3 years
of follow-up. Both were clinically mild cases in children with rel-
atively low PRNT titers before infection. A 4-fold increase in titer
compared to the previous year was observed in 5% to 10% of indi-
viduals each year.
Conclusion: This ﬁrst evaluation of antibody persistence after
CYD-TDV vaccination shows that neutralizing antibodies persist at
high titers for at least 3 years after last vaccination, possibly due
in part to natural exposure. Vaccinees who became infected with
dengue did not develop severe illness. This follow-up study and
similar studies in countries with different dengue epidemiology
are ongoing to further characterize the antibody persistence and
long term safety after CYD-TDV vaccination.
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